BACKGROUND: Patients with Ewing sarcoma require local primary tumor control with surgery, radiation, or both. The optimal choice of local control for overall and local disease control remains unclear. METHODS: Patients with localized Ewing sarcoma of bone who were treated on 3 consecutive protocols with standard-dose, 5-drug chemotherapy every 3 weeks were included (n=465). Propensity scores were used to control for differences between local control groups by constructing multivariate models to assess the impact of local control type on clinical endpoints (event-free survival [EFS], overall survival, local failure, and distant failure) independent of differences in their propensity to receive each local control type. RESULTS: Patients who underwent surgery were younger (P=.02) and had more appendicular tumors (P<.001). Compared with surgery, radiation had higher unadjusted risks of any event (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.18-2.44), death (HR, 1.84; 95% CI, 1.18-2.85), and local failure (HR, 2.57; 95% CI, 1.37-4.83). On multivariate analysis, compared with surgery, radiation had a higher risk of local failure (HR, 2.41; 95% CI, 1.24-4.68), although there were no significant differences in EFS (HR, 1.42; 95% CI, 0.94-2.14), overall survival (HR, 1.37; 95% CI, 0.83-2.26), or distant failure (HR, 1.13; 95% CI, 0.70-1.84) between local control groups. CONCLUSIONS: In this large group of similarly treated patients, choice of the mode of local control was not related significantly to EFS, overall survival, or distant failure, although the risk of local failure was greater for radiation compared with surgery. These data support surgical resection when appropriate, whereas radiotherapy remains a reasonable alternative in selected patients.
BACKGROUND:Patients with Ewing sarcoma require local primary tumor control with surgery, radiation, or both. The optimal choice of local control for overall and local disease control remains unclear. METHODS:Patients with localized Ewing sarcoma of bone who were treated on 3 consecutive protocols with standard-dose, 5-drug chemotherapy every 3 weeks were included (n=465). Propensity scores were used to control for differences between local control groups by constructing multivariate models to assess the impact of local control type on clinical endpoints (event-free survival [EFS], overall survival, local failure, and distant failure) independent of differences in their propensity to receive each local control type. RESULTS:Patients who underwent surgery were younger (P=.02) and had more appendicular tumors (P<.001). Compared with surgery, radiation had higher unadjusted risks of any event (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.18-2.44), death (HR, 1.84; 95% CI, 1.18-2.85), and local failure (HR, 2.57; 95% CI, 1.37-4.83). On multivariate analysis, compared with surgery, radiation had a higher risk of local failure (HR, 2.41; 95% CI, 1.24-4.68), although there were no significant differences in EFS (HR, 1.42; 95% CI, 0.94-2.14), overall survival (HR, 1.37; 95% CI, 0.83-2.26), or distant failure (HR, 1.13; 95% CI, 0.70-1.84) between local control groups. CONCLUSIONS: In this large group of similarly treated patients, choice of the mode of local control was not related significantly to EFS, overall survival, or distant failure, although the risk of local failure was greater for radiation compared with surgery. These data support surgical resection when appropriate, whereas radiotherapy remains a reasonable alternative in selected patients.
Authors: G Bacci; S Ferrari; F Bertoni; S Rimondini; A Longhi; P Bacchini; C Forni; M Manfrini; D Donati; P Picci Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Torunn I Yock; Mark Krailo; Christopher J Fryer; Sarah S Donaldson; James S Miser; Zhengjia Chen; Mark Bernstein; Fran Laurie; Mark C Gebhardt; Holcombe E Grier; Nancy J Tarbell Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: J Dunst; R Sauer; J M Burgers; R Hawliczek; R Kürten; W Winkelmann; M Salzer-Kuntschik; M Müschenich; H Jürgens Journal: Cancer Date: 1991-06-01 Impact factor: 6.860
Authors: Richard B Womer; Daniel C West; Mark D Krailo; Paul S Dickman; Bruce R Pawel; Holcombe E Grier; Karen Marcus; Scott Sailer; John H Healey; John P Dormans; Aaron R Weiss Journal: J Clin Oncol Date: 2012-10-22 Impact factor: 44.544
Authors: Linda Granowetter; Richard Womer; Meenakshi Devidas; Mark Krailo; Chenguang Wang; Mark Bernstein; Neyssa Marina; Patrick Leavey; Mark Gebhardt; John Healey; Robert Cooper Shamberger; Allen Goorin; James Miser; James Meyer; Carola A S Arndt; Scott Sailer; Karen Marcus; Elizabeth Perlman; Paul Dickman; Holcombe E Grier Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: J Dunst; H Jürgens; R Sauer; H Pape; M Paulussen; W Winkelmann; C Rübe Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: Jennifer L Pretz; Constance M Barysauskas; Suzanne George; Jason L Hornick; Chandrajit P Raut; Yen-Lin E Chen; Karen J Marcus; Edwin Choy; Francis Hornicek; John E Ready; Thomas F DeLaney; Elizabeth H Baldini Journal: Oncologist Date: 2017-05-26
Authors: Thomas Cash; Elizabeth McIlvaine; Mark D Krailo; Stephen L Lessnick; Elizabeth R Lawlor; Nadia Laack; Joel Sorger; Neyssa Marina; Holcombe E Grier; Linda Granowetter; Richard B Womer; Steven G DuBois Journal: Pediatr Blood Cancer Date: 2016-06-14 Impact factor: 3.167
Authors: Safia K Ahmed; R Lor Randall; Steven G DuBois; William S Harmsen; Mark Krailo; Karen J Marcus; Katherine A Janeway; David S Geller; Joel I Sorger; Richard B Womer; Linda Granowetter; Holcombe E Grier; Richard G Gorlick; Nadia N I Laack Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-24 Impact factor: 7.038